Bristol Myers Squibb shared on LinkedIn:
“Our work in thoracic oncology extends beyond advancing innovative science to helping ensure progress reaches patients. Lung cancer remains the leading cause of cancer deaths worldwide. Because it is often diagnosed at advanced stages, early detection and screening can play an important role for patients facing higher risk.
Across the lung cancer community, we collaborate with partners to educate healthcare providers, help address gaps in biomarker testing and work to overcome barriers to care.
This Lung Cancer Awareness Month, learn more about how we’re working to advance care for people with lung cancer.”
Watch the video attached to the post.
Bristol Myers Squibb’s Role in Lung Cancer Awareness Month
Bristol Myers Squibb marks Lung Cancer Awareness Month by highlighting its continued efforts to improve lung cancer prevention, early detection, and treatment. Through its research programs and collaborations with healthcare organizations and patient advocacy groups, the company works to raise awareness, support healthcare professionals, and address gaps in screening and biomarker testing.
It has funded community-based programs aimed at expanding access to screening, particularly in underserved areas where healthcare resources may be limited. One example is its support for the QUILS initiative, which aims to improve lung cancer screening programs in Mississippi and Nevada.
In January 2026, Bristol Myers Squibb partnered with Microsoft to explore the use of AI-powered radiology tools to detect potentially cancerous lung nodules in medical scans. The collaboration is intended to help identify lung cancer earlier, improve patient monitoring and follow-up, and make screening more accessible.
You may also be interested in: